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A greater understanding of the genes involved in antibiotic resistance in Mycobacterium
tuberculosis (Mtb) is necessary for the design of improved therapies. Clustered
regularly interspaced short palindromic repeat interference (CRISPRi) has been previously
utilized in mycobacteria to identify novel drug targets by the demonstration of gene
essentiality. The work presented here shows that it can also be usefully applied to
the study of non-essential genes involved in antibiotic resistance. The expression
of an ADP-ribosyltransferase (Arr) involved in rifampicin resistance in Mycobacterium
smegmatis was silenced using CRISPRi and the impact on rifampicin susceptibility was
measured. Gene silencing resulted in a decrease in the minimum inhibitory concentration
(MIC) similar to that previously reported in an arr deletion mutant. There is contradictory
evidence for the toxicity of Streptococcus pyogenes dCas9 (dCas9Spy) in the literature.
In this study the expression of dCas9Spy inM. smegmatis showed no impact on viability.
Silencing was achieved with concentrations of the aTc inducer lower than previously
described and with shorter induction times. Finally, designing small guide RNAs (sgRNAs)
that target transcription initiation, or the early stages of elongation had the most impact
on rifampicin susceptibility. This study demonstrates that CRISPRi based gene silencing
can be as impactful as gene deletion for the study of non-essential genes and further
contributes to the knowledge on the design and induction of sgRNAs for CRISPRi. This
approach can be applied to other non-essential antimicrobial resistance genes such as
drug efflux pumps.
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INTRODUCTION
Human pulmonary tuberculosis (TB) caused by Mtb remains
one of the most important infectious diseases in public health
worldwide. It is estimated that up to 1.5 million people die of TB
annually, making it the highest cause of death from an infectious
agent (Global tuberculosis report, 2020). Current TB treatments
involve long regimens with four antibiotics: rifampicin, isoniazid,
ethambutol and pyrazinamide and have associated side-effects.
The length of the treatment and frequent patient non-compliance
encourage the occurrence of multi-drug resistant (MDR) and
extremely drug resistant (XDR) TB with the emergence of
drug resistance in Mtb being a considerable public health crisis
hindering control and eradication programs (Dheda et al., 2017).
The discovery of new drugs and novel targets as well as efforts
to improve the efficacy of current available drugs are crucial to
control the global epidemic.
Essential genes are attractive novel drug targets, and the
demonstration of essentiality can require modulating the
expression of the putative essential gene in a merodiploid strain,
an approach that is time consuming, costly, and inefficient in
organisms such as mycobacteria that are particularly challenging
to genetically modify due to low frequencies of recombination
and slow growth (Choudhary et al., 2016). The CRISPRi system
overcomes a number of these challenges. A catalytically inactive
dCas9 protein is expressed and, guided by sgRNAs, targets a
specific gene sequence. The resulting complex binds to the
target sequence and sterically inhibits transcription initiation
or elongation (Larson et al., 2013). The CRISPRi/dCas9 system
has been utilized to study essential genes in a number of
bacteria including; Escherichia coli (Qi et al., 2013), Streptococcus
pneumoniae (Bikard et al., 2013), Streptomyces coelicolor (Tong
et al., 2015), Bacillus subtilis (Peters et al., 2016), Clostridium
acetobutylicum (Li et al., 2016), Corynebacterium glutamicum
(Cleto et al., 2016), Staphylococcus aureus (Zhao et al., 2017) and
Pseudomonas spp. (Tan et al., 2018).
Several papers have described the use of CRISPRi for
silencing of essential genes in mycobacteria. Choudhary et al.
(2015) introduced the CRISPRi approach in M. smegmatis,
Mycobacterium bovis BCG Pasteur and Mtb using a codon-
optimized S. pyogenes dCas9Spy. Singh et al. (2016) followed with
a similar CRISPRi/dCas9 system for use in Mtb, in this case
a two-plasmid system with dCas9Spy cloned into an integrative
plasmid under an anhydro-tetracycline (aTc) inducible promoter,
co-expressed with the sgRNA on a second plasmid. Additionally,
a single plasmid system using dCas9 derived from Streptococcus
thermophilus (dCas9Sth1) has also been developed and used to
silence several putative essential genes allowing the verification
of their suitability as drug targets (Rock et al., 2017; McNeil and
Cook, 2019).
The majority of previous studies have utilized this system
to silence the expression of putative essential drug-targets to
demonstrate their requirement for bacterial growth bymeasuring
the impact on the growth of the silenced strain. An alternative
approach in the search for new therapeutic strategies is to make
the current antibiotics more effective by targeting genes that are
not essential for growth but are involved in antibiotic resistance,
i.e., re-sensitizing antibiotic resistant strains. This approach has
recently been used in E. coli where sequence-specific targeting
an antibiotic efflux pump using peptide conjugated oligomers
not only restored antibiotic sensitivity in resistant strains, but
rendered strains hyper-sensitive allowing 2- to 40-fold lower
antibiotic doses (Ayhan et al., 2016). Given the time and costs
associated with the development of new drugs, the improvement
of the efficacy of the existing antimicrobials is a useful alternative
strategy. The silencing approach also holds promise as a way to
understand bacterial mechanisms of resistance.
In this study, we demonstrate the utilization of the CRISPRi
system to restore sensitivity to the antibiotic rifampicin in M.
smegmatis, a saprophytic species that is intrinsically resistant to
rifampicin due the presence of Arr, which inactivates rifampicin
by ribosylation (Dabbs et al., 1995). We measure the impact
of repression of the arr gene on sensitivity to rifampicin by
measuring the MIC in silenced strains. In addition, we measure
the effect of varying the concentration of the aTc inducer and the
position of the sgRNA in relation to the translational start site on
the MIC of rifampicin.
MATERIALS AND METHODS
Bacterial Growth and Culture Conditions
M. smegmatis strains were grown in Middlebrook 7H9 broth
supplemented with 0.2% glycerol, 0.05% Tween 80 (Sigma) and
10% albumin-dextrose-catalase (BD Diagnostics) at 37◦C on a
shaking platform or on Middlebrook 7H11 agar supplemented
with 10% oleic-albumin-dextrose-catalase (BD Diagnostics) at
37◦C for 3 days. For plasmid selection, antibiotics were used
at the following concentrations: kanamycin 25µg/ml (Sigma),
hygromycin 50µg/ml (Roche) and aTc 2-200 ng/ml (Sigma).
Bacterial growth was measured by monitoring the OD600 over
time and viability measurements were made using the Miles and
Misra technique; spotting 20 µl of a series of 10-fold dilutions of
culture onto agar (Miles et al., 1938).
Construction of sgRNA Expression
Plasmids and Strains
The strains and plasmids used in this study are given in
Table 1. pRH2502, an integrative plasmid expressing dCas9Spy
and pRH2521 expressing the sgRNA scaffold, both from Tet-
regulated promoters were acquired from Singh et al. (2016)
currently available on Addgene. sgRNAs targeting arr were
designed using a published protocol (Larson et al., 2013).
Protospacer adjacent motif (PAM) sites, “NGG,” upstream
and downstream of the annotated translational start site were
chosen:- 20 nucleotides downstream of each PAM were selected
as a potential genome specific sgRNA. The probability of
complementarity to any other region of the genome was analyzed
using a basic local alignment search tool (BLAST) (Altschul
et al., 1990). Sequences with full length matches specific to arr
were taken forward. A full length transcribed sgRNA including
the terminators and dCas9 handle was designed and M-fold
was used to predict the secondary structure of the full length
sgRNA transcript (Zuker, 2003). Candidates were selected which
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TABLE 1 | Strains and plasmids used in this study.
Strain/plasmid Genotype/Description Source
Strains
E. coli DH5α SupE44 1lacU169 (lacZ1M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Invitrogen
M. smegmatis mc2155 High-frequency transformation mutant ATCC 607 Snapper et al., 1990
MsmdCas9 M. smegmatis mc
2155 with integrative plasmid containing dcas9Spy (pRH2502), kan
R This study
MsmdCas9_control MsmdCas9 with non-integrative plasmid for inserting sgRNA (pRH2521). Empty vector control, kan
R, hygR This study
MsmdCas9_arr1 MsmdCas9 with plasmid containing sgRNA targeting between−47 bp and −28 bp upstream arr start codon (pSG_arr1)
kanR, hygR
This study
MsmdCas9_arr2 MsmdCas9 with sgRNA targeting between−27 bp and −8 bp upstream arr start codon (pSG_arr2), kan
R, hygR This study





pRH2502 Integrative plasmid derived from pTC-0X-1L, expressing dCas9Spy from an inducible tetRO promoter (uv15tetO) Singh et al., 2016
pRH2521 Non-integrative plasmid derived from pTE-10M-0X, expressing sgRNA from an inducible tetRO promoter (Pmyc1tetO) Singh et al., 2016
pSG_arr1 sgRNA targeting between −47 bp to −28 bp upstream of the arr start codon cloned into pRH2521 This study
pSG_arr2 sgRNA targeting between −27 bp to −8 bp upstream arr start codon cloned into pRH2521 This study
pSG_arr3 sgRNA targeting between +13 bp to +32 bp downstream of the arr start codon cloned into pRH2521 This study
pSG_oligo2 sgRNA targeting between −50 bp to −38 bp upstream of the arr start codon cloned into pRH2521 This study
pSG_oligo3 sgRNA targeting between −32 bp to −20 bp upstream of the arr start codon cloned into pRH2521 This study
pSG_oligo4 sgRNA targeting between +66 bp to +78 bp downstream of the arr start codon cloned into pRH2521 This study
pSG_oligo5 sgRNA targeting between −74 bp to −56 bp upstream of the arr start codon cloned into pRH2521 This study
pSG_oligo6 sgRNA targeting between −56 bp to −38 bp upstream of the arr start codon cloned into pRH2521 This study
pSG_oligo7 sgRNA targeting between +60 bp to +78 bp downstream of the arr start codon cloned into pRH2521 This study
pSG_oligo8 sgRNA targeting between +166 bp to +184 bp downstream of the arr start codon cloned into pRH2521 This study
pSG_oligo9 sgRNA targeting between −53 bp to −35 bp upstream of the arr start codon cloned into pRH2521 This study
pSG_oligo10 sgRNA targeting between −27 bp to −9 bp upstream of the arr start codon cloned into pRH2521 This study
The targeting region given does not include the 3 bp PAM site.
were predicted to fold into the dCas9Spy and terminator hairpin
loops. Complementary forward and reverse primers using the 20
nucleotide sequence (without the PAM) with appropriate ends
for ligation to the pRH2521 vector were designed. All forward
primers had “ggga” and all reverse primers had “aaac” added to
the 5′ end. Table 2 shows the list of oligonucleotides used to
construct the sgRNA plasmids and the strand targeted by each
oligonucleotide. Oligos were annealed and cloned into CRISRPi
plasmids using BbsI (NEB) as previously described (Choudhary
et al., 2015; Singh et al., 2016). One microgram of pRH2502
(dCas9Spy integrative vector) was electroporated at 25 kV, 25
µF with 1,000  resistance into electrocompetent M. smegmatis
mc2155, this strain was grown and further electroporated with
1 µg of pRH2521 expressing the targeted sgRNAs (Parish and
Stoker, 1998).
RNA Extraction
Total RNA was extracted as previously described (Rustad et al.,
2009). Cultures were grown to OD600 0.1–0.2 and induced with
0, 50 or 200 ng/ml of aTc for an hour, followed by centrifugation
at 2,000 x g at 4 ◦C for 5 min. Pellets were resuspended in
TRIzol (Sigma) on ice and added to 1.5 ml tubes containing
0.1 mm glass beads. Cells were disrupted by three cycles of
30 s pulses at speed 6,500 rpm using a Precellys homogenizer.
RNA was purified using a Qiagen RNeasy kit combined with
on-column DNase digestion according to the manufacturer’s
instructions. Quantity and quality were determined using a
DeNovix Spectrophotometer (DeNovix Inc, USA) and agarose
gel electrophoresis.
RT-qPCR
To remove traces of contaminating DNA, RNA samples
were treated with RNase-free DNase I (Invitrogen). cDNA
was synthesized from 100 ng of RNA using Superscript III
Reverse transcriptase (ThermoFisher) according tomanufacturer
instructions. In order to quantify the expression of arr, qPCRs
were performed using PowerUp SYBR Green Master Mix
(ThermoFisher) with 1 µl of cDNA and 0.3 µM of either sigA
primers or arr primers (Table 2) in a final volume of 20 µl.
Samples were run on a BioRad CFX96 analyser at 50 ◦C for
2 min, 95 ◦C for 2 min, followed by 39 cycles of 95 ◦C for 15 s,
60 ◦C for 1min and 75 ◦C for 30 s. The mRNA levels of arr were
normalized against the mRNA of the reference gene sigA. Three
biological replicates were run, with technical duplicates. Melting
curve analysis was carried out to verify specificity.
MIC Determinations
To quantify the susceptibility to rifampicin, a broth
microdilution assay using resazurin dye was carried out
(Agrawal et al., 2015). Hundred microliter of twice the required
concentration of rifampicin was serial diluted across 96-well
microtiter plates. Cultures were grown to exponential phase
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TABLE 2 | Primers used in this study.
Oligonucleotide name Sequence Strand targeted Region targeted relative to arr start
CRISPRi Oligonucleotides
arr1_Forward GGGACGGAACGCCGATTGTGCACC Coding strand −47 bp to −28 bp upstream
arr1_Reverse AAACGGTGCACAATCGGCGTTCCG
arr2_Forward GGGACCCCCTGTTCCGTGTGTGAT Coding strand −27 bp to −8 bp upstream
arr2_Reverse AAACATCACACACGGAACAGGGGG
arr3_Forward GGGATGCACTTCGAACGGTTTCGG Coding strand +13 bp to +32 bp downstream
arr3_Reverse AAACCCGAAACCGTTCGAAGTGCA
Oligo 2_Forward GGGACCGGGTGCACAAT Non-coding −50 bp to −38 bp upstream
Oligo 2_Reverse AAACATTGTGCACCCGG
Oligo 3_Forward GGGATTCCGATCACACA Non-coding −32 bp to −20 bp upstream
Oligo 3_Reverse AAACTGTGTGATCGGAA
Oligo 4_Forward GGGAGAGCTCAAGGTGG Non-coding +66 bp to +78 bp downstream
Oligo 4_Reverse AAACCCACCTTGAGCTC
Oligo 5_Forward GGGATGGGGCTTGCGGCAAGGCC Non-coding −74 bp to −56 bp upstream
Oligo 5_Reverse AAACGGCCTTGCCGCAAGCCCCA
Oligo 6_Forward GGGACCGGTGCCGGGTGCACAAT Non-coding −56 bp to −38 bp upstream
Oligo 6_Reverse AAACATTGTGCACCCGGCACCGG
Oligo 7_Forward GGGAAAGGCCGAGCTCAAGGTGG Non-coding +60 bp to +78 bp downstream
Oligo 7_Reverse AAACCCACCTTGAGCTCGGCCTT
Oligo 8_Forward GGGAAGTTCGGCACCCCACACCG Coding +166 bp to +184 bp downstream
Oligo 8_Reverse AAACCGGTGTGGGGTGCCGAACT
Oligo 9_Forward GGGACCGATTGTGCACCCGGCAC Coding −53 bp to −35 bp upstream
Oligo 9_Reverse AAACGTGCCGGGTGCACAATCGG







These are underlined in the table first four bases in each of the CRISPRi primer sets are used for cloning the sgRNA into pRH2521. The region targeted does not include the 3 bp PAM
site.
(OD600 0.4–0.6), diluted to an OD600 of 0.1 and 100µl was added
to each well. This represents ∼106 cells. 2–200 ng/ml of aTc for
CRISPRi/dCas9-mediated repression of arr gene expression was
added where required. Plates were incubated at 37 ◦C for 40 h.
Following incubation, 30 µl of 0.2 mg/ml resazurin was added
to each well and incubated at 37 ◦C for an additional 24 h and
fluorescence was measured using a Tecan microplate reader at
excitation 560 nm and emission 590 nm. Images of the plates
were also taken.
RESULTS
CRISPRi Targeting of the Promoter Region
of the arr Gene in M. smegmatis Increases
the Susceptibility to Rifampicin
Inhibition of the expression of arr is expected to potentiate
growth inhibition in the presence of rifampicin. In order to
determine which region should be targeted for CRISPRi, nine
sgRNAs of different lengths were designed, targeting regions
in both the promoter and coding sequences of the gene, on
either the coding or non-coding strand (Figure 1A). Unlike
other bacteria, mycobacteria use more commonly leaderless
transcripts during gene expression, however, the arr gene has
been shown to contain a 5′ UTR indicating the presence of
a putative Shine-Dalgarno sequence (Cortes et al., 2013; Shell
et al., 2015; Martini et al., 2019). Previous RNAseq studies have
shown that transcription starts 31 bp upstream of the GTG
annotated translational start codon (Shell et al., 2015). Putative
−35 and −10 regions were predicted using Softberry BPROM
(Solovyev and Salamov, 2011) and sgRNAs were designed to
include coverage of these regions. The location of the sgRNAs,
alongside the transcription and translational start sites and
putative promoter elements is given in Figure 1A. Growth
inhibition in the presence of rifampicin after induction of the
various sgRNAs is shown in Figure 1B.
At 24 h, all M. smegmatis strains containing an sgRNA
targeting arr, apart from those targeting regions 4 and 6,
Frontiers in Microbiology | www.frontiersin.org 4 February 2021 | Volume 11 | Article 619427
Faulkner et al. CRISPRi Re-sensitizes Mycobacteria to Rifampicin
FIGURE 1 | CRISPRi targeting of the arr gene (MSMEG_1221) over various sites in the promoter results in increased susceptibility to rifampicin (A) Position of the
sgRNA targets. Nine sgRNAs (2-10) were designed to target both non-coding (sgRNAs 2-7) and coding strands (8-10). sgRNAs targeting the coding strand are
indicated by a dashed line. The gene specific region has mainly 19 bp, except for sgRNAs 2 and 3 where a 13 bp region was targeted. The transcriptional start site is
indicated by a * and the translation start GTG is in bold. Putative −10 and −35 promoter elements are highlighted in gray. (B) Growth of M. smegmatis sgRNA-dCas9
strains in 7H9 growth medium supplemented with aTc (200 ng/ml) and rifampicin (3µg/ml). Optical density (OD600) was measured at 24, 48, and 72 h. Numbers refer
to the sgRNA oligos as listed in Table 2. Statistical significance was determined using One-way ANOVA with Dunnett’s multiple comparisons test against the
dCas9-only strain for each time point (****p < 0.0001, ***p < 0.001, **p < 0.01). Error bars represent standard deviation from the mean of triplicate repeats.
exhibited increased susceptibility (p < 0.05) to rifampicin
compared to the control strain expressing only dCas9Spy. At
48 h, M. smegmatis strains containing sgRNAs targeting regions
2, 5, 9, and 10 still displayed significantly increased susceptibility
and this endured for a further 24 h for regions 5 and 9. The
shorter sgRNAs which were 13 bp long, targeting regions 2
and 3 were less effective than the 19 bp long sgRNAs. sgRNAs
targeting region 5 and 9, at the promoter region were the most
effective, with targeting of the −10 (sgRNA 9) region being the
most impactful.
CRISPRi Targeting of arr in the Absence of
Rifampicin Results in Reduction of Gene
Expression but Does Not Impact Growth
Three further sgRNAs were designed (arr1, arr2, and arr3) that
targeted a 20 bp gene specific region designed to cover the
putative −10 region (arr1), the 5′ UTR (arr2) and the 5′ end
of the coding sequence (arr3) (Figure 2A). All sgRNAs were
designed to target the coding strand. The impact of induction of
sgRNAs arr1, arr2 and arr3 alongside dCas9 on the expression
of the arr gene was measured using RT-qPCR. Expression levels
were normalized to sigA and expressed relative to the uninduced
cultures. The results are shown in Figure 2B. Induction of arr1
and arr3 with aTc at 50 ng/ml led to more than 50% reduction in
the expression of the arr gene. Induction of arr2 with 50 ng/ml of
aTc resulted in 40% reduction in its expression. Induction with
higher levels of aTc (arr1, arr3 with 200 ng/ml) did not improve
inhibition of arr expression.
As arr is a non-essential gene, inhibition of its expression
is not expected to influence the growth of the bacteria. To test
this, we compared the effect of the induction with aTc on the
growth of MsmdCas9_arr1 and MsmdCas9_arr2. Additionally, we
compared the impact of CRISPRi induction on the growth of
the MsmdCas9_control strain which does not contain a targeting
sgRNA. The results (Figure 2C) show that there is no growth
inhibitory effect as a result of induction of the CRISPRi system
Initial studies using dCas9 from S. pyogenes to repress
expression of a number of essential genes reported no toxicity
in mycobacteria (Choudhary et al., 2015; Singh et al., 2016).
However, a subsequent study reported toxicity (Rock et al.,
2017). Given the discrepancies over the reports of toxicity in
the literature, the effect of induction of dCas9Spy on the viability
of M. smegmatis mc2155 was evaluated. M. smegmatis cultures
expressing dCas9Spy (MsmdCas9_control) were induced with 50
and 200 ng/ml of aTc and compared to non-induced cultures and
the wild type strain. The results, which are shown in Figure 3,
indicate that induction of with aTc does not result in toxicity.
CRISPRi Targeting arr Sensitizes
M. smegmatis to Rifampicin
An initial qualitative screen on solid media demonstrated
that silencing of arr by induction of the sgRNAs with
a range of aTc concentrations (50-200 ng/ml) sensitized M.
smegmatis to rifampicin (Supplementary Figure 1). In order to
quantify the effect of arr silencing on rifampicin sensitivity,
the MIC of rifampicin for MsmdCas9_arr1, MsmdCas9_arr2 and
MsmdCas9_arr3 was determined without aTc and with aTc
at 50 ng/ml and 200 ng/ml (Table 3, Supplementary Figure 2).
Induction of the CRISPRi system using aTc had no impact on
the MIC of the wild type strain, mc2155. The MIC obtained
(1.6–3.12µg/ml) is in-line with previously reported values [0.8–
3.9µg/ml (Agrawal et al., 2015; Gupta et al., 2015)]. The non-
induced cultures and the MsmdCas9_control showed the same
MIC as the wild type strain, mc2155 (Supplementary Figure 2
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FIGURE 2 | CRISPRi targeting of the non-essential gene arr (MSMEG_1221) in M. smegmatis results in transcriptional inhibition but does not impact growth. (A)
Position of sgRNA targets on the arr gene. Three sgRNAs were designed to target arr, indicated by dashed lines. arr1 targeted −47 to −28, arr2 targeted −27 to −8
bp upstream of the annotated translational start codon. arr3 targeted +13 to +32 bp within the coding sequence. The transcriptional start site is indicated by a * and
the translation start site (GTG) is in bold. The putative−10 promoter element predicted using Softberry BPROM is highlighted in gray. (B) Inhibition of arr expression in
cultures expressing sgRNA targeting arr, induced with different concentration of aTc. mRNA levels are expressed relative to the control strain expressing dCas9 only.
Results are the mean of three independent biological replicates and expression levels were measured in duplicate for each concentration of aTc (*p < 0.05,
**p < 0.01, ***p < 0.001); (C) Growth of M. smegmatis expressing either sgRNA targeting arr or dCas9 only with differing levels of aTc. Cultures were grown in 96 well
plates from a starting OD600 in a total volume of 200 µl.
wells 2-5). However, at 50 ng/ml and 200 ng/ml aTc there
was a clear decrease in the MIC of rifampicin for the three
strains (MsmdCas9_arr1,MsmdCas9_arr2 andMsmdCas9__arr3) to
0.2µg/ml with 50 ng/ml of aTc and 0.8µg/ml with 200 ng/ml of
aTc. The reduction in MIC due to the induction of the sgRNAs
with 50 ng/ml and 200 ng/ml of aTc were 8–16 and 2–4-fold,
respectively (Table 3). Deletion of the arr gene in M. smegmatis
has been reported to decrease the MIC of rifampicin by 16-fold,
similar to induction with 50 ng/ml of aTc (Agrawal et al., 2015).
Lower Levels of aTc Can Be Used to
Sensitize the Strains to Rifampicin
To investigate whether sensitization to rifampicin could be
achieved using lower concentrations of aTc, the MIC of
rifampicin for the strains MsmdCas9_control, MsmdCas9_arr1
and MsmdCas9_arr2 were measured in the presence of 4 ng/ml,
6 ng/ml and 8 ng/ml of aTc and compared to non-induced
cultures. The results, which are displayed as a change in
fluorescence at different concentrations of rifampicin, show
that without induction, all the three strains have the same
MIC (1.6µg/ml, Figure 4). However, a 2-fold reduction in the
MIC is achieved at 4, 6 and 8 ng/ml of aTc. This suggests
that silencing of arr by induction of the sgRNA can take
place at concentrations as low as 4 ng/ml, although the impact
on the level of sensitization is less than that observed at
higher concentrations.
DISCUSSION
In this study, we demonstrate the usefulness of CRISPRi silencing
for the study of genes that are not essential for growth, but
encode targets associated with antibiotic resistance. Induction of
dCas9Spy in arr targeting strains with 50 and 200 ng/ml of aTc
decreased the MIC of rifampicin and re-sensitizedM. smegmatis
to the antibiotic by 8-16 and 2-4-fold, respectively.M. smegmatis,
which is intrinsically resistant to rifampicin due to the expression
of arr, has previously been shown to be a useful surrogate for
pathogenic mycobacteria to study antimicrobial susceptibility
(Chaturvedi et al., 2007). Additionally, as rifampicin is used for
the treatment of several mycobacterial infections, arr seemed
to be a suitable target to examine the potential use of the
CRISPRi/dCas9 system to explore genes which could be targeted
to improve the efficacy of current antibiotics. This approach can
now be used to study genes in other intrinsically rifampicin-
resistant species such as Mycobacterium abscessus, a pathogenic
fast growing mycobacterial species. Interestingly, M. abscessus
also carries a putative arr gene and its role in intrinsic rifampicin
resistance was previously demonstrated through deletion of arr
(Rominski et al., 2017). The work presented here demonstrates
that gene silencing can be used effectively in mycobacterial
species to study intrinsic drug resistance.
In this study we show that CRISPRi/dCas9 can be used to
restore sensitivity to rifampicin inM. smegmatis by silencing the
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FIGURE 3 | Induction of dCas9Spy in M. smegmatis mc
2155 is not toxic to the cells. (A) Miles and Misra spotting to examine the impact of induction of dCas9 on the
viability of M. smegmatis mc2155. Broth cultures of Msm_WT and MsmdCas9_control strains were grown overnight at 37
◦C and diluted to OD600 0.01. Cultures were
further diluted: 1- 10−1, 2- 10−2, 3- 10−3, 4- 10−4 as labeled, and spotted using Miles and Misra on 7H11 agar supplemented with 0, 50, and 200 ng/ml of aTc. (B)
The CFU/ml was estimated from colony counts.
TABLE 3 | Fold change in the MIC due to inhibition of arr expression.
Strains MIC of rifampicin (µg/ml) MIC fold change
0ng/ml aTc 50ng/ml aTc 200ng/ml aTc 50ng/ml aTc 200ng/ml aTc
mc2155 1.6–3.12 1.6–3.12 1.6–3.12 - -
MsmdCas9_arr1 1.6–3.12 0.2 0.8 8–16 2–4
MsmdCas9_arr2 1.6–3.12 0.2 0.8 8–16 2–4
MsmdCas9_arr3 1.6–3.12 0.2 0.8 8–16 2–4
expression of arr. As little as 40–60% reduction in expression of
arr resulted in an 8–16-fold decrease in theMIC. Previous studies
using an 1arr strain reported a 16-fold decrease in the MIC
(Agrawal et al., 2015). This suggests that, for arr at least, silencing
can be as effective as deletion as the levels of susceptibility
reached were similar to that previously reported. Although the
1arr strain from the Agrawal study was not included here, the
congruity of the MIC measurements in the wild type strains
between this study and the study by Agrawal et al. validates
our approach. To our knowledge there are no other isogenic
1arr mutants to which a comparison could be made. Although,
another1arr strain ofM. smegmatis has been described, this is in
a different genetic background, therefore not comparable to this
study (Combrink et al., 2007).
Similar to previous reports (Larson et al., 2013), the findings
of this study show that gene silencing using dCas9Spy is most
effective if the target site is within the promoter region on the
coding or non-coding strand of the gene of interest inhibiting
transcription initiation. Targeting regions 5 and 9, both of which
were within the promoter region, on the non-coding and coding
strand respectively, was most impactful in comparison to the
other target regions (Figure 1B). Additionally, targeting region
9, which include the putative −10 sequence, produced the most
sustained impact on growth 24, 48, and 72 h post-induction.
Strategies to inhibit the elongation of transcription (rather than
transcription initiation) are reported to be most effective when
targeting the coding strand of the protein coding region or the
5′ UTR (Larson et al., 2013). These are represented by sgRNAs
10 and 8 (coding) with sgRNAs 4 and 7 targeting the non-coding
strand. Of those sgRNAs targeting sites beyond the transcription
start site, sgRNA 10 was the most effective in improving the
susceptibility to rifampicin thereby supporting the strategy of
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FIGURE 4 | Induction of dCas9Spy with low concentrations of aTc sensitizes MsmdCas9_arr1 and MsmdCas9_arr2 to rifampicin. 96 well microtiter plates were filled with
100 µl of twice the required concentration of rifampicin and serial diluted in two-fold across the plates. Approximately 106 bacterial cells were added to each well with
antibiotics containing (A) 0 ng/ml (B) 4 ng/ml (C) 6 ng/ml and (D) 8 ng/ml of aTc. Plates were incubated at 37◦C for 40 h after which 30 µl of 0.2 mg/ml resazurin were
added to each well and incubated at 37◦C for an additional 24 h. Fluorescence was measured on a Tecan plate reader at 560 nm (excitation) and 590 nm (emission).
targeting the coding strand. The results further showed that the
shorter sgRNAs (sgRNAs 2, 3, and 4) were less effective than
longer sequences.
The three main sgRNAs used in this study were designed to
target the putative −10 region (arr1), the 5′ UTR (arr2) and
the 5′ end of the coding sequence (arr3), with all three being
20 bp long. The impact of induction of the system for 1 h with
0, 50 and 200 ng/ml of aTc was measured using RT-qPCR. arr
expression was suppressed by 40–60% (Figure 2B). Previous
studies have measured levels of silencing by CRISPRi/dCas9Spy
12–24 h post-induction with aTc. Singh et al. (2016) reported
a 60–80% reduction in sigH and pknB expression following
induction with 200 ng/ml of aTc for 12 h (Singh et al., 2016).
This study shows that gene silencing can take place within
1 h of induction. Additionally, the data presented here show
that 200 ng/ml of aTc did not improve gene silencing and
sensitization compared to 50 ng/ml (Figure 2B and Table 3). In
M. smegmatis, the TetR-regulated UVtetO promoter has been
reported to achieve the peak of induction with 50–100 ng/ml of
aTc with decreasing levels of induction at concentrations higher
than 100 ng/ml (Ehrt et al., 2005) and this could explain our
observations at 200 ng/ml. Furthermore, this study also shows
that induction with lower concentrations (4–8 ng/ml) of aTc is
sufficient to decrease the MIC of rifampicin (Figure 4). One
study indicated that dCas9Spy expression is potentially toxic in
mycobacteria (Rock et al., 2017). Toxicity of dCas9Spy has also
been reported in E. coli upon very high levels of expression (Cho
et al., 2018). However, similar to other reports (Choudhary et al.,
2015, 2019; Singh et al., 2016), the work presented here shows that
the induction of dCas9Spy does not impactM. smegmatis growth
and viability.
These results show that the CRISPRi system can be used
to target, and knock-down genes involved in antimicrobial
resistance, enabling faster reverse genetics compared to
gene knockout techniques. There are limitations, given the
requirement for induction by aTc, however, the system has great
potential for multiplexing which will be useful in the study of
redundancy. In particular, it will be useful in the study of multiple
drug efflux pumps in slow-growing pathogenic mycobacterial
genomes where sequential mutagenesis is not efficient. The
approach can improve studies on gene function and resistance to
current and future antimicrobials.
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Supplementary Figure 1 | CRISPRi targeting of arr sensitizes M. smegmatis to
rifampicin. The bacterial cultures were grown to saturation for 48 h in 7H9 and
streaked on 7H11 agar plates containing different concentrations of aTc (50
ng/ml-200 ng/ml) as indicated. Plates contained rifampicin at 2µg/ml. Plates were
incubated at 37◦C for 48 h before being photographed.
Supplementary Figure 2 | Induction of dCas9Spy in arr targeting strains
decreases the MIC of rifampicin. Ninety-Six well microtiter plates were filled with
100 µl of twice the required concentration of rifampicin and serially diluted in
2-fold across the plates. Approximately 106 bacterial cells were added to wells
with antibiotics and (A) 0 ng/ml (B) 50 ng/ml (C) 200 ng/ml of aTc. Plates were
incubated at 37◦C for 40 h after which 30 µl of 0.2 mg/ml resazurin was added to
each well and incubated at 37◦C for an additional 24 h. Fluorescence was
measured on a Tecan plate reader at 560 nm (excitation) and 590 nm (emission)
and images taken. Pink wells indicate bacterial growth whereas blue wells indicate
inhibition of growth in the presence of rifampicin. Images shown are representative
of one replicate for each treatment. The MIC is determined as the concentration of
rifampicin at which the first well in the row appears pink.
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